CU24680B1 - Derivados de espirocromano como moduladores del receptor de acetilcolina nicotínica alfa7 - Google Patents

Derivados de espirocromano como moduladores del receptor de acetilcolina nicotínica alfa7

Info

Publication number
CU24680B1
CU24680B1 CU2020000108A CU20200108A CU24680B1 CU 24680 B1 CU24680 B1 CU 24680B1 CU 2020000108 A CU2020000108 A CU 2020000108A CU 20200108 A CU20200108 A CU 20200108A CU 24680 B1 CU24680 B1 CU 24680B1
Authority
CU
Cuba
Prior art keywords
spirochroman
modulators
derivatives
acetylcholine receptor
alfa7
Prior art date
Application number
CU2020000108A
Other languages
English (en)
Other versions
CU20200108A7 (es
Inventor
Molnár Katalin Dudásné
János Éles
Anita Horváth
István Ledneczki
György István Lévay
Zsolt Némethy
Pál Tapolcsányi
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of CU20200108A7 publication Critical patent/CU20200108A7/es
Publication of CU24680B1 publication Critical patent/CU24680B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

<p>La invención se refiere a derivados de espirocromano de fórmula (I):</p> <p>ESPACIO PARA FÓRMULA</p> <p>Los compuestos de la presente invención pueden ser útiles para tratar afecciones mediadas por moduladores de la actividad del receptor de acetilcolina nicotínica Alfa7, que incluye principalmente enfermedades asociadas al sistema nervioso central (SNC), tales como esquizofrenia, enfermedad de Alzheimer, esclerosis lateral amiotrófica, entre otras.</p>
CU2020000108A 2018-07-13 2019-07-12 Derivados de espirocromano como moduladores del receptor de acetilcolina nicotínica alfa7 CU24680B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HUP1800248A HU231333B1 (hu) 2018-07-13 2018-07-13 Spirokromán származékok
PCT/IB2019/055948 WO2020012422A1 (en) 2018-07-13 2019-07-12 Spirochromane derivatives

Publications (2)

Publication Number Publication Date
CU20200108A7 CU20200108A7 (es) 2021-07-02
CU24680B1 true CU24680B1 (es) 2023-10-06

Family

ID=89992725

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2020000108A CU24680B1 (es) 2018-07-13 2019-07-12 Derivados de espirocromano como moduladores del receptor de acetilcolina nicotínica alfa7

Country Status (24)

Country Link
US (1) US20210330650A1 (es)
EP (1) EP3820869B1 (es)
JP (1) JP7487167B2 (es)
KR (1) KR20210033002A (es)
CN (1) CN112823157B (es)
AR (1) AR115782A1 (es)
AU (1) AU2019300514B2 (es)
BR (1) BR112020026996A2 (es)
CA (1) CA3104258A1 (es)
CL (1) CL2021000080A1 (es)
CO (1) CO2021001216A2 (es)
CU (1) CU24680B1 (es)
EA (1) EA202190245A1 (es)
ES (1) ES2964617T3 (es)
GE (2) GEAP202315557A (es)
HU (2) HU231333B1 (es)
IL (1) IL279938B2 (es)
MX (1) MX2021000460A (es)
MY (1) MY206779A (es)
PE (1) PE20211809A1 (es)
PH (1) PH12020552183A1 (es)
SG (1) SG11202012594RA (es)
TW (1) TWI821321B (es)
WO (1) WO2020012422A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU231414B1 (hu) 2018-07-13 2023-08-28 Richter Gedeon Nyrt. Tiadiazin származékok
TWI901650B (zh) 2020-03-26 2025-10-21 匈牙利商羅特格登公司 啶及吡啶并〔３，４－ｃ〕嗒衍生物
CN115403579A (zh) * 2021-05-27 2022-11-29 上海拓界生物医药科技有限公司 一种新的螺环衍生物及其用途
HU231691B1 (hu) 2021-09-29 2025-10-28 Richter Gedeon Nyrt GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok
WO2025175249A1 (en) 2024-02-14 2025-08-21 Olema Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006016548A1 (ja) 2004-08-09 2006-02-16 Eisai R & D Management Co., Ltd. ヘテロ環化合物を含有する新規な抗マラリア剤
NZ566036A (en) 2005-09-13 2010-06-25 Janssen Pharmaceutica Nv 2-Aniline-4-aryl substituted thiazole derivatives that modulate the alpha7 nicotinic receptor
TW200813067A (en) * 2006-05-17 2008-03-16 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
CN101490056A (zh) * 2006-05-17 2009-07-22 阿斯利康(瑞典)有限公司 烟碱乙酰胆碱受体的配体101
WO2008082490A2 (en) 2006-12-20 2008-07-10 Schering Corporation Novel jnk inhibitors
ES2443290T3 (es) 2007-10-04 2014-02-18 F. Hoffmann-La Roche Ag Derivados arilamida sustituidos con tetrazol y usos de los mismos
WO2009043784A1 (en) 2007-10-04 2009-04-09 F. Hoffmann-La Roche Ag Cyclopropyl aryl amide derivatives and uses thereof
BRPI0907492A2 (pt) 2008-02-07 2017-06-13 Abbott Lab derivados amida como moduladores alostéricos positivos e métodos de sua utilização
MY152486A (en) 2008-03-19 2014-10-15 Janssen Pharmaceutica Nv Trisubstituted 1,2,4 - triazoles as nicotinic acetylcholine receptor modulators
EP2110377A1 (en) * 2008-04-15 2009-10-21 DAC S.r.l. Spirocyclic derivatives as histone deacetylase inhibitors
CL2009000916A1 (es) * 2008-04-17 2010-12-31 Glaxo Group Ltd Compuestos derivados de 2-trifluorometil-1h-indol-5-metilcarboxamida, moduladores del receptor nicotinico de acetilcolina alfa7 (nachr); composicon farmaceutica; y uso para el tratamiento del deterioro cognitivo y de un trastorno psicotico como esquizofrenia.
WO2009135944A1 (en) 2008-05-09 2009-11-12 Janssen Pharmaceutica Nv Trisubstituted pyrazoles as acetylcholine receptor modulators
AU2009260519A1 (en) 2008-05-30 2009-12-23 Merck Sharp & Dohme Corp. Novel substituted azabenzoxazoles
RS61281B1 (sr) 2009-12-31 2021-02-26 Hutchison Medipharma Ltd Sintetički intermedijer koristan u pripremi triazolopiridinskih c-met inhibitora
US8829026B2 (en) 2010-10-01 2014-09-09 Raqualia Pharma Inc. Sulfamoyl benzoic acid heterobicyclic derivatives as TRPM8 antagonists
US9617210B2 (en) 2013-03-13 2017-04-11 Lupin Limited Pyrrole derivatives as alpha 7 NACHR modulators
GEAP202014908A (en) * 2016-03-22 2020-03-10 Merck Sharp & Dohme Allosteric modulators of nicotinic acetylcholine receptors
EP3534888B1 (en) 2016-11-01 2022-04-06 Merck Sharp & Dohme Corp. Substituted bicyclic heteroaryl allosteric modulators of nicotinic acetylcholine receptors
WO2018112204A1 (en) * 2016-12-14 2018-06-21 Cephalon, Inc. Spiropiperidine derivatives

Also Published As

Publication number Publication date
PE20211809A1 (es) 2021-09-14
EP3820869B1 (en) 2023-08-30
TW202035399A (zh) 2020-10-01
KR20210033002A (ko) 2021-03-25
CN112823157A (zh) 2021-05-18
JP2021531260A (ja) 2021-11-18
MX2021000460A (es) 2021-06-23
TWI821321B (zh) 2023-11-11
IL279938A (en) 2021-03-01
CN112823157B (zh) 2024-08-09
GEAP202315557A (en) 2023-05-10
MY206779A (en) 2025-01-07
US20210330650A1 (en) 2021-10-28
AU2019300514A1 (en) 2021-02-11
HUP1800248A2 (en) 2020-01-28
CA3104258A1 (en) 2020-01-16
SG11202012594RA (en) 2021-02-25
CU20200108A7 (es) 2021-07-02
AR115782A1 (es) 2021-02-24
CL2021000080A1 (es) 2021-10-29
IL279938B2 (en) 2025-01-01
PH12020552183A1 (en) 2021-06-21
HUE064417T2 (hu) 2024-03-28
WO2020012422A1 (en) 2020-01-16
ES2964617T3 (es) 2024-04-08
EA202190245A1 (ru) 2021-04-20
AU2019300514B2 (en) 2023-02-02
CO2021001216A2 (es) 2021-02-26
GEP20237534B (en) 2023-09-11
BR112020026996A2 (pt) 2021-04-06
IL279938B1 (en) 2024-09-01
EP3820869A1 (en) 2021-05-19
HU231333B1 (hu) 2023-01-28
JP7487167B2 (ja) 2024-05-20

Similar Documents

Publication Publication Date Title
DOP2018000204A (es) Moduladores alostéricos de receptores de acetilcolina nicotínicos
CL2010000129A1 (es) Compuestos derivados de benzazepinas fusionadas sustituidas, moduladores del receptor de acetilcolina; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento de trastornos del snc tales como esquizofrenia, demencia, enfermedad del alzheimer, esclerosis multiple, entre otras.
CO6751271A2 (es) Imidazol[5,1-f][1,2,4]triazinas para el tratamiento de trastornos neurológicos
MX2019000231A (es) Derivados de 5,7-dihidro-pirrolo-piridina para tratar enfermedades neurologicas y neurodegenerativas.
DOP2015000009A (es) Antagonistas del receptor de 5-ht3
UY36126A (es) ?compuestos de 6,8-dioxabiciclo[3.2.1]octano-2,3-diol sustituidos como agentes de direccionamiento al asgpr?.
AR123407A1 (es) Un proceso para la fabricación de (6ar,10ar)-7-propil-6,6a,7,8,9,10,10a,11-octahidro-[1,3]dioxolo[4’,5’:5,6]benzo[1,2-g]quinolina y (4ar,10ar)-1-propil-1,2,3,4,4a,5,10,10a-octahidro-benzo[g]quinolina-6,7-diol
UY35628A (es) ?compuestos heteroaromáticos y su uso como ligandos d1 de dopamina?.
NI201400014A (es) Inhibidores de pde10 de pirimidina
CL2013003731A1 (es) Compuestos derivados de carboxamida; composición farmacéutica que los comprende, y su uso como inhibidores de la fosfodiesterasa tipo 10a (pde10a) para el tratamiento de trastornos del snc, esquizofrenia, disfunción cognitiva relacionada con la esquizofrenia, trastornos bipolares, depresión, disfunción cognitiva, alteraciones cognitivas, trastornos del comportamiento asociados a la enfermedad de alzheimer, obesidad, enfermedad de huntington y ansiedad.
PE20181853A1 (es) 1,5-dihidro-4h-pirazolo[3,4-d]pirimidin-4-onas y 1,5-dihidro-4h-pirazolo[4,3-c]piridin-4-onas como inhibidores de pde1
BR112019004243A2 (pt) composto, composição farmacêutica, método para inibição de quinase do zíper de leucina dupla, método para tratamento de uma doença mediada por quinase do zíper de leucina dupla e método para obter um efeito em um paciente
NI202000074A (es) Moduladores alostéricos de espiropiperidina de receptores nicotínicos de acetilcolina
MX2019000980A (es) Compuestos y composiciones y usos de los mismos.
MX2018014114A (es) Derivados del sobetiroma.
BR112016024936A2 (pt) moduladores de gpr40 à base de pirrolidina para tratamento de doenças como diabetes
CL2015000559A1 (es) Compuestos derivados de 2-oxo-2,3-dihidro-indoles; su proceso de obtencion; composicion y combinacion farmaceutica que los comprende; y su uso para el tratamiento de trastornos del snc que son sintomas positivos o negativos de la esquizofrenia, el abuso de sustancias, la adiccion a alcohol y las drogas, enfermedad de alzheimer, enfermedad de parkinson, entre otras.
ECSP12012023A (es) 3,6-diazabiciclo [3.1.1] heptanos como ligandos de receptores nicotínicos neuronales de acetilcolina
MX2018008653A (es) Ligandos d3 de dopamina 6,7,8,9-tetrahidro-5h-pirido[2,3-d]azepina .
MX2019000982A (es) Compuestos y composiciones y usos de los mismos.
TW201612169A (en) (R)-3-((3s,4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders
UY32385A (es) Amidas de pirazinona sustituida
MA37999A1 (fr) Dérivés de macrolide, leur préparation et leur utilisation thérapeutique
UY34281A (es) &#34;1,4-diazabiciclo[3.2.2]nonanos como ligandos de receptores nicotínicos neuronales de acetilcolina
CO7160011A2 (es) Compuestos de azetidina y piperidina útiles como inhibidores de pde10